Remedent, Inc. (REMI)
USD 0.02
(-23.66%)
USD 0.02
(-23.66%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 3.04 Million USD | 6.55% |
| 2023 | 2.85 Million USD | 5.76% |
| 2022 | 2.69 Million USD | -2.02% |
| 2021 | 2.75 Million USD | -4.64% |
| 2020 | 2.88 Million USD | 18.67% |
| 2019 | 2.43 Million USD | 14.44% |
| 2018 | 2.12 Million USD | 36.99% |
| 2017 | 1.55 Million USD | -54.79% |
| 2016 | 3.43 Million USD | -0.25% |
| 2015 | 3.44 Million USD | -10.6% |
| 2014 | 3.84 Million USD | -23.62% |
| 2013 | 5.03 Million USD | -0.39% |
| 2012 | 5.05 Million USD | -23.22% |
| 2011 | 6.58 Million USD | 64.39% |
| 2010 | 4 Million USD | 3.65% |
| 2009 | 3.86 Million USD | 3.63% |
| 2008 | 3.73 Million USD | 2.48% |
| 2007 | 3.64 Million USD | 17.27% |
| 2006 | 3.1 Million USD | 71.77% |
| 2005 | 1.8 Million USD | -22.05% |
| 2004 | 2.31 Million USD | 36.22% |
| 2003 | 1.7 Million USD | -99.89% |
| 2002 | 1.51 Billion USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 3.04 Million USD | 1.04% |
| 2024 FY | 3.04 Million USD | 6.55% |
| 2024 Q3 | 3 Million USD | 9.64% |
| 2024 Q2 | 2.74 Million USD | -2.0% |
| 2024 Q1 | 2.8 Million USD | -1.86% |
| 2023 Q4 | 2.85 Million USD | 6.8% |
| 2023 Q1 | 2.6 Million USD | 0.0% |
| 2023 FY | 2.85 Million USD | 5.76% |
| 2023 Q2 | 2.52 Million USD | -3.06% |
| 2023 Q3 | 2.67 Million USD | 5.73% |
| 2022 FY | 2.69 Million USD | -2.02% |
| 2021 Q3 | 2.91 Million USD | 0.29% |
| 2021 FY | 2.75 Million USD | -4.64% |
| 2021 Q2 | 2.9 Million USD | 1.42% |
| 2021 Q1 | 2.86 Million USD | -0.66% |
| 2020 Q2 | 2.78 Million USD | 4.02% |
| 2020 Q4 | 2.88 Million USD | 3.45% |
| 2020 FY | 2.88 Million USD | 18.67% |
| 2020 Q3 | 2.79 Million USD | 0.16% |
| 2020 Q1 | 2.67 Million USD | 10.1% |
| 2019 FY | 2.43 Million USD | 14.44% |
| 2019 Q1 | 2.1 Million USD | -0.97% |
| 2019 Q2 | 2.15 Million USD | 2.48% |
| 2019 Q3 | 2.23 Million USD | 3.79% |
| 2019 Q4 | 2.43 Million USD | 8.65% |
| 2018 Q4 | 2.12 Million USD | 12.43% |
| 2018 Q3 | 1.89 Million USD | 14.76% |
| 2018 FY | 2.12 Million USD | 36.99% |
| 2018 Q2 | 1.64 Million USD | 11.8% |
| 2018 Q1 | 1.47 Million USD | -5.03% |
| 2017 Q3 | 3.36 Million USD | -1.31% |
| 2017 Q1 | 3.38 Million USD | -1.53% |
| 2017 Q2 | 3.4 Million USD | 0.76% |
| 2017 FY | 1.55 Million USD | -54.79% |
| 2017 Q4 | 1.55 Million USD | -53.83% |
| 2016 Q3 | 3.34 Million USD | 1.31% |
| 2016 Q1 | 3.28 Million USD | -4.52% |
| 2016 Q2 | 3.3 Million USD | 0.44% |
| 2016 Q4 | 3.43 Million USD | 2.67% |
| 2016 FY | 3.43 Million USD | -0.25% |
| 2015 Q3 | 3.31 Million USD | -2.85% |
| 2015 FY | 3.44 Million USD | -10.6% |
| 2015 Q4 | 3.44 Million USD | 3.87% |
| 2015 Q1 | 3.58 Million USD | -6.96% |
| 2015 Q2 | 3.41 Million USD | -4.77% |
| 2014 Q1 | 4.67 Million USD | -7.33% |
| 2014 Q2 | 4.53 Million USD | -2.83% |
| 2014 Q3 | 4.62 Million USD | 1.83% |
| 2014 Q4 | 3.84 Million USD | -16.7% |
| 2014 FY | 3.84 Million USD | -23.62% |
| 2013 Q3 | 5.6 Million USD | 6.16% |
| 2013 Q2 | 5.27 Million USD | -1.85% |
| 2013 Q1 | 5.37 Million USD | 6.28% |
| 2013 FY | 5.03 Million USD | -0.39% |
| 2013 Q4 | 5.03 Million USD | -10.05% |
| 2012 FY | 5.05 Million USD | -23.22% |
| 2012 Q2 | 8.04 Million USD | 8.52% |
| 2012 Q3 | 5.72 Million USD | -28.92% |
| 2012 Q4 | 5.05 Million USD | -11.54% |
| 2012 Q1 | 7.41 Million USD | 12.53% |
| 2011 Q2 | 5.67 Million USD | 13.88% |
| 2011 FY | 6.58 Million USD | 64.39% |
| 2011 Q4 | 6.58 Million USD | 25.46% |
| 2011 Q3 | 5.25 Million USD | -7.5% |
| 2011 Q1 | 4.98 Million USD | 24.38% |
| 2010 FY | 4 Million USD | 3.65% |
| 2010 Q4 | 4 Million USD | -10.76% |
| 2010 Q1 | 4.16 Million USD | 7.81% |
| 2010 Q2 | 3 Million USD | -28.02% |
| 2010 Q3 | 4.49 Million USD | 49.65% |
| 2009 Q3 | 3.6 Million USD | -27.33% |
| 2009 FY | 3.86 Million USD | 3.63% |
| 2009 Q4 | 3.86 Million USD | 7.3% |
| 2009 Q2 | 4.95 Million USD | 31.39% |
| 2009 Q1 | 3.77 Million USD | 1.15% |
| 2008 Q3 | 3.13 Million USD | 21.79% |
| 2008 Q4 | 3.73 Million USD | 19.18% |
| 2008 Q2 | 2.57 Million USD | -41.25% |
| 2008 Q1 | 4.37 Million USD | 20.17% |
| 2008 FY | 3.73 Million USD | 2.48% |
| 2007 FY | 3.64 Million USD | 17.27% |
| 2007 Q4 | 3.64 Million USD | -4.71% |
| 2007 Q2 | 3.84 Million USD | 49.78% |
| 2007 Q3 | 3.82 Million USD | -0.58% |
| 2007 Q1 | 2.56 Million USD | -17.36% |
| 2006 Q3 | 2.59 Million USD | 101.83% |
| 2006 Q4 | 3.1 Million USD | 19.69% |
| 2006 Q2 | 1.28 Million USD | -26.03% |
| 2006 Q1 | 1.73 Million USD | -3.88% |
| 2006 FY | 3.1 Million USD | 71.77% |
| 2005 Q3 | 1.35 Million USD | -10.35% |
| 2005 Q2 | 1.5 Million USD | 7.93% |
| 2005 FY | 1.8 Million USD | -22.05% |
| 2005 Q1 | 1.39 Million USD | -39.75% |
| 2005 Q4 | 1.8 Million USD | 33.72% |
| 2004 Q3 | 2.22 Million USD | 8.01% |
| 2004 Q1 | 1.5 Million USD | -11.76% |
| 2004 FY | 2.31 Million USD | 36.22% |
| 2004 Q4 | 2.31 Million USD | 4.19% |
| 2004 Q2 | 2.06 Million USD | 37.17% |
| 2003 Q1 | 1.48 Million USD | -2.07% |
| 2003 Q2 | 1.34 Million USD | -9.53% |
| 2003 FY | 1.7 Million USD | -99.89% |
| 2003 Q4 | 1.7 Million USD | 7.95% |
| 2003 Q3 | 1.57 Million USD | 17.39% |
| 2002 Q3 | 1.82 Million USD | 15.97% |
| 2002 Q2 | 1.57 Million USD | 40.39% |
| 2002 Q1 | 1.12 Million USD | 2.76% |
| 2002 FY | 1.51 Billion USD | 0.0% |
| 2002 Q4 | 1.51 Million USD | -17.02% |
| 2001 Q3 | 1.03 Million USD | 12.29% |
| 2001 Q2 | 921.3 Thousand USD | 0.21% |
| 2001 Q4 | 1.09 Million USD | 5.58% |
| 2001 Q1 | 919.33 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.34 Million USD | -29.384% |
| Ansell Limited | 1.32 Billion USD | 99.771% |
| Ansell Limited | 1.33 Billion USD | 99.772% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 126.33 Million USD | 97.593% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 943.17 Thousand USD | -222.351% |
| Psykey, Inc. | 2.47 Million USD | -22.89% |
| ConvaTec Group Plc | 2.01 Billion USD | 99.849% |
| ConvaTec Group Plc | 2.02 Billion USD | 99.85% |
| Encision Inc. | 1.98 Million USD | -53.245% |
| Golden Valley Development, Inc | - USD | -Infinity% |
| Hear AtLast Holdings, Inc. | 3.04 Million USD | 0.005% |
| Innovative MedTech Inc. | 6.13 Million USD | 50.442% |
| LifePoint, Inc. | 2.45 Million USD | -23.884% |
| Medite Cancer Diagnostics, Inc. | 10.18 Million USD | 70.137% |
| Paradigm Medical Industries, Inc. | 3.4 Million USD | 10.579% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Reflect Scientific, Inc. | 776.32 Thousand USD | -291.628% |
| SmileDirectClub, Inc. | 982.26 Million USD | 99.69% |
| Sector 10, Inc. | 9.84 Million USD | 69.119% |
| Shandong Weigao Group Medical Polymer Company Limited | 1.35 Billion USD | 99.776% |
| SheerVision, Inc. | 1.43 Million USD | -112.402% |
| United Health Products, Inc. | 1.99 Million USD | -52.102% |
| Vasamed, Inc. | 1 Million USD | -202.429% |
| Wearable Health Solutions, Inc. | 3.8 Million USD | 19.998% |
| Yubo International Biotech Limited | 2.91 Million USD | -4.338% |